相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype for updates and increased immunogenicity
Chengming Liu et al.
CANCER LETTERS (2020)
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Misako Nagasaka et al.
CANCER TREATMENT REVIEWS (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D
Malcolm J. W. Sim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Nitin Roper et al.
CELL REPORTS MEDICINE (2020)
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
Badi El Osta et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Helen Adderley et al.
EBIOMEDICINE (2019)
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Matthias Scheffler et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Tissue-Specific Oncogenic Activity of KRASA146T
Emily J. Poulin et al.
CANCER DISCOVERY (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang et al.
FRONTIERS IN ONCOLOGY (2019)
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
R S Herbst et al.
ANNALS OF ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Phenotypic Switching of Naive T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS
Arjun Kalvala et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Francesco Passiglia et al.
BRITISH JOURNAL OF CANCER (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
Lilan Yi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
KRAS4A directly regulates hexokinase 1
Caroline R. Amendola et al.
NATURE (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Differential Effector Engagement by Oncogenic KRAS
Tina L. Yuan et al.
CELL REPORTS (2018)
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure
David A. Barbie et al.
CLINICAL LUNG CANCER (2018)
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
Jonathan Wade Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses
Jasmin Quandt et al.
ONCOIMMUNOLOGY (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Inhibition of RAS function through targeting an allosteric regulatory site
Russell Spencer-Smith et al.
NATURE CHEMICAL BIOLOGY (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Frances A. Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
P2.07-052 Detection of KRAS Mutation in Blood Predicts Favorable Response to Immunotherapy in NSCLC
M. Dietrich et al.
Journal of Thoracic Oncology (2017)
Fatty Acid Synthase Is a Therapeutic Target in Mutant KRAS Lung Cancer
C. Bartolacci et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
David R. Gandara et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma
Arvin M. Gouw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640
Gerald Falchook et al.
CANCER RESEARCH (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Qiong J. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
C. A. Carter et al.
ANNALS OF ONCOLOGY (2016)
FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study
Marie O'Farrell et al.
CANCER RESEARCH (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer
Megan L. Hames et al.
LUNG CANCER (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
Wei Pan et al.
ONCOTARGET (2016)
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
Andreas H. Scheel et al.
ONCOIMMUNOLOGY (2016)
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer A Review
Kevin Wood et al.
JAMA ONCOLOGY (2016)
Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.
Emma Jane Dean et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
E. Rulli et al.
ANNALS OF ONCOLOGY (2015)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox et al.
CLINICAL CANCER RESEARCH (2015)
Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Frederick D. Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma
Junichi Soh et al.
ONCOLOGY LETTERS (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy
Anna K. Brady et al.
ONCOTARGET (2015)
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
Mirko Marabese et al.
ONCOTARGET (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma
Benjamin Izar et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Ernest Nadal et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
MEK inhibition in non-small cell lung cancer
Thomas E. Stinchcombe et al.
LUNG CANCER (2014)
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
Dickran Kazandjian et al.
ONCOLOGIST (2014)
US Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
Sean Khozin et al.
ONCOLOGIST (2014)
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zehua Zhu et al.
CANCER DISCOVERY (2014)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer with a KRAS Mutation
Anne-Marie C. Dingemans et al.
CLINICAL CANCER RESEARCH (2013)
KRAS Mutations in Advanced Nonsquamous Non-Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value
Wouter W. Mellema et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
Daquan Meng et al.
LUNG CANCER (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
Thomas F. Gajewski et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
M. C. Garassino et al.
ANNALS OF ONCOLOGY (2011)
Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
J. Matthew Reinersman et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians
Wei Zhou et al.
Chinese Journal of Cancer (2011)
Targeting protein prenylation for cancer therapy
Norbert Berndt et al.
NATURE REVIEWS CANCER (2011)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
Yihua Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
John D. Hainsworth et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells
Ken Takezawa et al.
CANCER RESEARCH (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2008)
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
Minh D. To et al.
NATURE GENETICS (2008)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features
IYS Tam et al.
CLINICAL CANCER RESEARCH (2006)
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma
ES Kim et al.
CANCER (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
C Mascaux et al.
BRITISH JOURNAL OF CANCER (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
JV Heymach et al.
ANNALS OF ONCOLOGY (2004)
Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
T Kosaka et al.
CANCER RESEARCH (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of the farnesyl transferase inhibitor r115777 in patients with advanced non-small-cell lung cancer
AA Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
